Annual EBITDA
-$269.98 M
-$61.90 M-29.75%
31 March 2024
Summary:
Immunovant annual earnings before interest, taxes, depreciation & amortization is currently -$269.98 million, with the most recent change of -$61.90 million (-29.75%) on 31 March 2024. During the last 3 years, it has fallen by -$161.93 million (-149.86%). IMVT annual EBITDA is now -311.27% below its all-time high of -$65.64 million, reached on 31 March 2020.IMVT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$115.65 M
-$21.45 M-22.77%
30 September 2024
Summary:
Immunovant quarterly earnings before interest, taxes, depreciation & amortization is currently -$115.65 million, with the most recent change of -$21.45 million (-22.77%) on 30 September 2024. Over the past year, it has dropped by -$53.91 million (-87.31%). IMVT quarterly EBITDA is now -28913400.00% below its all-time high of -$400.00, reached on 31 March 2019.IMVT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$352.17 M
-$53.91 M-18.08%
30 September 2024
Summary:
Immunovant TTM earnings before interest, taxes, depreciation & amortization is currently -$352.17 million, with the most recent change of -$53.91 million (-18.08%) on 30 September 2024. Over the past year, it has dropped by -$106.31 million (-43.24%). IMVT TTM EBITDA is now -88041150.00% below its all-time high of -$400.00, reached on 31 March 2019.IMVT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IMVT EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -29.8% | -87.3% | -43.2% |
| 3 y3 years | -149.9% | -207.4% | -175.1% |
| 5 y5 years | - | -10000.0% | -10000.0% |
IMVT EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -149.9% | at low | -207.4% | at low | -175.1% | at low |
| 5 y | 5 years | -311.3% | at low | <-9999.0% | at low | <-9999.0% | at low |
| alltime | all time | -311.3% | at low | <-9999.0% | at low | <-9999.0% | at low |
Immunovant EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$115.65 M(+22.8%) | -$352.17 M(+18.1%) |
| June 2024 | - | -$94.20 M(+16.6%) | -$298.25 M(+10.5%) |
| Mar 2024 | -$269.98 M(+29.7%) | -$80.81 M(+31.4%) | -$269.98 M(+6.6%) |
| Dec 2023 | - | -$61.49 M(-0.4%) | -$253.37 M(+3.1%) |
| Sept 2023 | - | -$61.74 M(-6.3%) | -$245.85 M(+5.2%) |
| June 2023 | - | -$65.92 M(+2.7%) | -$233.68 M(+12.3%) |
| Mar 2023 | -$208.08 M(+33.5%) | -$64.20 M(+18.9%) | -$208.08 M(+8.9%) |
| Dec 2022 | - | -$53.98 M(+8.9%) | -$191.06 M(+7.1%) |
| Sept 2022 | - | -$49.57 M(+22.9%) | -$178.32 M(+7.2%) |
| June 2022 | - | -$40.33 M(-14.5%) | -$166.38 M(+6.7%) |
| Mar 2022 | -$155.91 M | -$47.19 M(+14.4%) | -$155.91 M(+13.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | - | -$41.24 M(+9.6%) | -$137.62 M(+7.5%) |
| Sept 2021 | - | -$37.62 M(+26.0%) | -$128.00 M(+15.0%) |
| June 2021 | - | -$29.86 M(+3.3%) | -$111.34 M(+3.0%) |
| Mar 2021 | -$108.05 M(+64.6%) | -$28.89 M(-8.6%) | -$108.05 M(+8.3%) |
| Dec 2020 | - | -$31.62 M(+50.9%) | -$99.76 M(+26.3%) |
| Sept 2020 | - | -$20.96 M(-21.1%) | -$78.96 M(+35.2%) |
| June 2020 | - | -$26.58 M(+29.0%) | -$58.42 M(+82.9%) |
| Mar 2020 | -$65.64 M | -$20.60 M(+90.4%) | -$31.94 M(+181.8%) |
| Dec 2019 | - | -$10.82 M(+2477.4%) | -$11.33 M(+2111.2%) |
| Sept 2019 | - | -$419.80 K(+354.8%) | -$512.50 K(+452.9%) |
| June 2019 | - | -$92.30 K(>+9900.0%) | -$92.70 K(>+9900.0%) |
| Mar 2019 | - | -$400.00 | -$400.00 |
FAQ
- What is Immunovant annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Immunovant?
- What is Immunovant annual EBITDA year-on-year change?
- What is Immunovant quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Immunovant?
- What is Immunovant quarterly EBITDA year-on-year change?
- What is Immunovant TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Immunovant?
- What is Immunovant TTM EBITDA year-on-year change?
What is Immunovant annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of IMVT is -$269.98 M
What is the all time high annual EBITDA for Immunovant?
Immunovant all-time high annual earnings before interest, taxes, depreciation & amortization is -$65.64 M
What is Immunovant annual EBITDA year-on-year change?
Over the past year, IMVT annual earnings before interest, taxes, depreciation & amortization has changed by -$61.90 M (-29.75%)
What is Immunovant quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of IMVT is -$115.65 M
What is the all time high quarterly EBITDA for Immunovant?
Immunovant all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$400.00
What is Immunovant quarterly EBITDA year-on-year change?
Over the past year, IMVT quarterly earnings before interest, taxes, depreciation & amortization has changed by -$53.91 M (-87.31%)
What is Immunovant TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of IMVT is -$352.17 M
What is the all time high TTM EBITDA for Immunovant?
Immunovant all-time high TTM earnings before interest, taxes, depreciation & amortization is -$400.00
What is Immunovant TTM EBITDA year-on-year change?
Over the past year, IMVT TTM earnings before interest, taxes, depreciation & amortization has changed by -$106.31 M (-43.24%)